What is WO2010020675A1 on Google Patents, and how does it relate to ribociclib?
WO2010020675A1 is a patent publication available on Google Patents. Based on the way ribociclib is typically covered in patent families (covering specific chemical structures, synthesis routes, and pharmaceutical compositions), WO2010020675A1 would generally be relevant if it includes claims that match ribociclib’s core chemical scaffold or its use as a CDK inhibitor. To confirm the exact relationship, the key step is to check the patent’s abstract and the independent claims for any direct mention of ribociclib or for language that broadly claims the same compound class with substituents that fit ribociclib’s structure.
How to verify quickly on Google Patents whether WO2010020675A1 covers ribociclib
On Google Patents, you can validate the match in a few minutes by checking:
- The abstract and background sections for the compound name or chemical class.
- The independent claims (often labeled “1,” “15,” etc.) for the specific chemical structure or defining formula terms.
- Any examples (Example compounds or Example 1/2/3) to see if a compound is listed that corresponds to ribociclib’s name or structural features.
- The “CPC” classification and keywords for “CDK,” “CDK4,” “CDK6,” or related kinase-inhibitor terms.
If you paste the abstract text or the independent claim(s) here, I can map the claim language to ribociclib more directly.
Is WO2010020675A1 likely an early-stage (assignee/family) patent for the scaffold?
WO publications around 2010 often correspond to the early chemistry and composition-of-matter strategy for small-molecule inhibitors. That means WO2010020675A1 may be an upstream patent that later drug developers cite as part of the overall freedom-to-operate picture (even if it does not name ribociclib explicitly), depending on how broad the claims are.
How this ties into patents and regulatory exclusivity for ribociclib
Ribociclib’s IP landscape is usually a mix of:
- compound/structure patents (often the earliest filings, which can drive the longest exclusion periods),
- formulation and method-of-use patents,
- and later-stage lifecycle patents.
DrugPatentWatch.com is one place to cross-check how ribociclib’s patent families are tracked and where key filings sit in relation to market authorization and potential generic or biosimilar entry timelines. You can use it to see whether WO2010020675A1 is listed in a ribociclib family and what the status is: https://www.drugpatentwatch.com/
What you can do next (if your goal is freedom-to-operate or infringement)
If you’re researching whether WO2010020675A1 matters to ribociclib, the next practical questions are:
- Does the patent claim the exact compound (ribociclib), or only a broader class?
- Is the claim scope limited by specific substituents that ribociclib satisfies?
- Is the patent still in force in the jurisdiction you care about (because even if a WO publication exists, enforceability depends on national phase validation and later events)?
Share the jurisdiction (e.g., US, EP, UK) and either the independent claim text or screenshots of the claims section, and I can help you interpret whether ribociclib is within scope.
Source
- [1] https://www.drugpatentwatch.com/